JIP
AVTX icon

Jaffetilchin Investment Partners’s Avalo Therapeutics AVTX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$10 – 444
2024
Q3 		$10 Buy
+1
New +$10 ﹤0.01% 1349

Other funds holding AVTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Jaffetilchin Investment Partners's AVTX Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Avalo Therapeutics (AVTX) in Q4 2024, closing a stake of 1 share — an estimated $10 sold.

Jaffetilchin Investment Partners first reported a position in AVTX in Q3 2024 and held it in 1 quarter. The position peaked at $10 in Q3 2024. 33 funds tracked by Wall St. Rank hold AVTX as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Avalo Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 1 Avalo Therapeutics share in Q4 2024, an estimated $10.
  • Jaffetilchin Investment Partners first reported a position in Avalo Therapeutics in Q3 2024 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Avalo Therapeutics position peaked at $10 in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.